STERIS (STE)
(Delayed Data from NYSE)
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Bruker (BRKR) Stock Rises on Strong Preliminary Q4 Show
by Zacks Equity Research
Bruker's (BRKR) revenue growth is expected to beat expectations for the fourth quarter and 2019.
Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.
STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.
IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y
by Zacks Equity Research
The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.
CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.
Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.
Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.
Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.
Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid
by Zacks Equity Research
We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.
AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Align Technology (ALGN) Earnings Beat in Q4, Margins Rise
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.
Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.
PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.
DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add STERIS (STE) to Portfolio Now
by Zacks Equity Research
Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.
NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Steris (STE) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.
Steris (STE) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 4.76% and 2.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.